Stories
Tracy's story
Tracy’s daughter Jaz tested positive for type 1 autoantibodies. Early detection brings anxiety but also hope. The Registry offers vital support, research opportunities, and pathways to delay or ease future diagnosis.
Lisa and Jack's story
Jack’s early Type 1 diabetes diagnosis prevented hospital admission. Ongoing monitoring, support, and insulin improved his health. A national registry is vital for tracking progression, research, trials, and prevention strategies.
News
MHRA approves teplizumab to delay progression of type 1 diabetes
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teplizumab (Tzield) to delay the onset of Stage 3 type 1 diabetes (T1D) by an average of three years in adults and children aged 8 years and older with Stage 2 T1D, making it the UK’s first-ever approved immunotherapy for type 1 diabetes.
New trial opening soon in the UK
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Ash speaks at Talking About Diabetes (TAD) conference
On 28th June 2025, PPI advisor Ash spoke at the TAD conference in Liverpool, discussing his experience of screening, diagnosis, and Type 1 Diabetes. He introduced the UK Islet Autoantibody registry, sparking lively conversation and support.
Identifying Children at Risk of Type 1 Diabetes – Podcast with Dr Rachel Besser
Dr Rachel Besser explains how new treatment options mean it is now important to identify children before they develop symptomatic Type 1 diabetes. Rachel is working to ensure testing for risk of Type 1 diabetes is done in the best way for children and their families.
UK’s first registry to be set up for those at risk of type 1 diabetes
Researchers from the Oxford BRC and other collaborating organisations have received funding to set up a UK registry for children and adults who are at risk of type 1 diabetes and have tested positive for diabetes autoantibodies.